2Seventy Bio IncNASDAQ:TSVT
- LAST PRICE4.8000
- TODAY'S CHANGE (%)-0.2000 (-4.0000%)
- Bid / Lots4.7000/ 2
- Ask / Lots5.0000/ 10
- Open / Previous Close4.9900 / 5.0000
- Day Range
- 52 Week Range
- Volume239,829
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | TSVT |
|---|---|---|
| 09:32 ET | 11693 | 4.995 |
| 09:36 ET | 6615 | 4.98 |
| 09:38 ET | 300 | 4.98 |
| 09:43 ET | 1963 | 5 |
| 09:45 ET | 161 | 5.015 |
| 09:48 ET | 1000 | 5.02 |
| 09:50 ET | 1074 | 5.02 |
| 09:52 ET | 2202 | 4.98 |
| 09:57 ET | 100 | 4.9899 |
| 09:59 ET | 200 | 4.99 |
| 10:06 ET | 600 | 4.97 |
| 10:10 ET | 300 | 4.97 |
| 10:14 ET | 300 | 4.9724 |
| 10:15 ET | 400 | 4.9799 |
| 10:19 ET | 100 | 4.97 |
| 10:21 ET | 100 | 4.9799 |
| 10:26 ET | 200 | 4.9899 |
| 10:30 ET | 10846 | 4.98 |
| 10:32 ET | 586 | 4.984 |
| 10:33 ET | 100 | 4.9976 |
| 10:39 ET | 328 | 4.97 |
| 10:42 ET | 100 | 4.97 |
| 10:46 ET | 2079 | 5 |
| 10:48 ET | 100 | 5 |
| 10:51 ET | 137 | 5.01 |
| 10:55 ET | 8461 | 4.9999 |
| 11:00 ET | 9847 | 5.01 |
| 11:04 ET | 943 | 4.9957 |
| 11:13 ET | 100 | 4.98 |
| 11:15 ET | 400 | 4.97 |
| 11:18 ET | 100 | 4.9799 |
| 11:24 ET | 200 | 4.955 |
| 11:26 ET | 330 | 4.95 |
| 11:29 ET | 2614 | 4.97 |
| 11:31 ET | 1012 | 4.96 |
| 11:38 ET | 100 | 4.95 |
| 11:40 ET | 200 | 4.95 |
| 11:44 ET | 300 | 4.95 |
| 11:45 ET | 302 | 4.95 |
| 11:47 ET | 200 | 4.95 |
| 11:54 ET | 131 | 4.95 |
| 11:58 ET | 200 | 4.95 |
| 12:00 ET | 400 | 4.95 |
| 12:02 ET | 500 | 4.95 |
| 12:03 ET | 166 | 4.95 |
| 12:05 ET | 100 | 4.945 |
| 12:07 ET | 357 | 4.94 |
| 12:12 ET | 137 | 4.94 |
| 12:14 ET | 114 | 4.94 |
| 12:18 ET | 100 | 4.9499 |
| 12:20 ET | 2126 | 4.95 |
| 12:21 ET | 400 | 4.95 |
| 12:27 ET | 216 | 4.95 |
| 12:30 ET | 100 | 4.9599 |
| 12:32 ET | 100 | 4.95 |
| 12:34 ET | 1075 | 4.949 |
| 12:36 ET | 300 | 4.95 |
| 12:38 ET | 300 | 4.95 |
| 12:39 ET | 609 | 4.9599 |
| 12:43 ET | 1352 | 4.94 |
| 12:45 ET | 669 | 4.9499 |
| 12:48 ET | 300 | 4.93 |
| 12:50 ET | 200 | 4.92 |
| 12:52 ET | 100 | 4.92 |
| 12:54 ET | 800 | 4.9225 |
| 12:56 ET | 200 | 4.93 |
| 12:57 ET | 103 | 4.925 |
| 12:59 ET | 300 | 4.9299 |
| 01:01 ET | 500 | 4.93 |
| 01:03 ET | 100 | 4.92 |
| 01:06 ET | 2129 | 4.9199 |
| 01:12 ET | 1000 | 4.9 |
| 01:14 ET | 600 | 4.88 |
| 01:17 ET | 100 | 4.9099 |
| 01:19 ET | 1630 | 4.88 |
| 01:28 ET | 100 | 4.88 |
| 01:30 ET | 100 | 4.8899 |
| 01:33 ET | 119 | 4.88 |
| 01:35 ET | 1206 | 4.86 |
| 01:44 ET | 7904 | 4.84 |
| 01:53 ET | 955 | 4.83 |
| 02:00 ET | 305 | 4.82 |
| 02:09 ET | 490 | 4.78 |
| 02:11 ET | 2600 | 4.75 |
| 02:13 ET | 500 | 4.73 |
| 02:15 ET | 1620 | 4.74 |
| 02:18 ET | 5021 | 4.75 |
| 02:20 ET | 237 | 4.75 |
| 02:22 ET | 1000 | 4.75 |
| 02:24 ET | 113 | 4.73 |
| 02:26 ET | 5504 | 4.7556 |
| 02:27 ET | 500 | 4.7578 |
| 02:29 ET | 518 | 4.7508 |
| 02:31 ET | 100 | 4.75 |
| 02:36 ET | 202 | 4.73 |
| 02:40 ET | 100 | 4.72 |
| 02:42 ET | 117 | 4.72 |
| 02:44 ET | 100 | 4.73 |
| 02:47 ET | 1440 | 4.74 |
| 02:49 ET | 1700 | 4.75 |
| 02:51 ET | 200 | 4.7448 |
| 02:54 ET | 552 | 4.74 |
| 02:56 ET | 613 | 4.7499 |
| 02:58 ET | 2626 | 4.7749 |
| 03:00 ET | 1600 | 4.775 |
| 03:02 ET | 795 | 4.77 |
| 03:03 ET | 788 | 4.77 |
| 03:05 ET | 1067 | 4.7899 |
| 03:07 ET | 200 | 4.78 |
| 03:09 ET | 200 | 4.78 |
| 03:14 ET | 6222 | 4.76 |
| 03:20 ET | 500 | 4.75 |
| 03:21 ET | 1800 | 4.76 |
| 03:23 ET | 4102 | 4.78 |
| 03:25 ET | 200 | 4.79 |
| 03:27 ET | 1128 | 4.785 |
| 03:32 ET | 1071 | 4.78 |
| 03:36 ET | 100 | 4.78 |
| 03:39 ET | 500 | 4.77 |
| 03:41 ET | 2655 | 4.765 |
| 03:43 ET | 1531 | 4.785 |
| 03:45 ET | 1000 | 4.78 |
| 03:48 ET | 200 | 4.785 |
| 03:50 ET | 1121 | 4.78 |
| 03:52 ET | 816 | 4.78 |
| 03:54 ET | 2527 | 4.78 |
| 03:56 ET | 1000 | 4.775 |
| 03:57 ET | 1511 | 4.78 |
| 03:59 ET | 32961 | 4.8 |
May 9, 2024
DJ 2seventy bio Is Maintained at Buy by Canaccord Genuity, from 3:18PM ET on Thursday May 09, 2024 by Dow Jones
3:18PM ET on Thursday May 09, 2024 by Dow Jones
May 8, 2024
Press Release: 2seventy bio Reports First Quarter Financial Results and Recent Operational Progress, from 7:02AM ET on Wednesday May 08, 2024 by Dow Jones
7:02AM ET on Wednesday May 08, 2024 by Dow Jones2seventy bio Reports First Quarter Financial Results and Recent Operational Progress, from 7:00AM ET on Wednesday May 08, 2024 by Dow Jones
7:00AM ET on Wednesday May 08, 2024 by Dow Jones
May 3, 2024
Press Release: 2seventy bio to Report First Quarter 2024 Financial Results on May 8, 2024, from 7:07AM ET on Friday May 03, 2024 by Dow Jones
7:07AM ET on Friday May 03, 2024 by Dow Jones2seventy bio to Report First Quarter 2024 Financial Results on May 8, 2024, from 7:00AM ET on Friday May 03, 2024 by Dow Jones
7:00AM ET on Friday May 03, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
2Seventy Bio Inc | 257.0M | -1.1x | --- |
CytomX Therapeutics Inc | 155.8M | 9.6x | --- |
Chromadex Corp | 262.9M | -70.2x | --- |
G1 Therapeutics Inc | 244.7M | -7.4x | --- |
Enanta Pharmaceuticals Inc | 276.6M | -1.9x | --- |
Rigel Pharmaceuticals Inc | 172.3M | -8.4x | --- |
Company Information
2seventy bio, Inc. is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer. The Company is focused on the commercialization and development of Abecma (idecabtagene vicleucel). Abecma is its B cell maturation antigen (BCMA)-targeted CAR T cell therapy for multiple myeloma, in collaboration with their partner Bristol Myers Squibb (BMS). ABECMA is a BCMA-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. Abecma uses a lentiviral vector (LVV), to deliver a chimeric antigen receptor (CAR), with the potential to program a patient’s own T cells to recognize the plasma cell specific BCMA, protein on the cell surface.
Contact Information
- Headquarters
- 60 Binney StreetCAMBRIDGE, MA, United States 02210
- Phone
- 339-499-9300
- Fax
- 302-636-5454
Executives
- Independent Chairman of the Board
- Daniel Lynch
- President, Chief Executive Officer, Director
- Nick Leschly
- Chief Financial Officer, Chief Operating Officer
- William Baird
- Independent Director
- Eli Casdin
- Independent Director
- Sarah Glickman
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $257.0M |
|---|---|
Revenue (TTM) | $71.2M |
Shares Outstanding | 51.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-4.34 |
Book Value | $5.04 |
P/E Ratio | -1.1x |
Price/Sales (TTM) | 3.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -332.93% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
